Expanding Treatable Patient Populations with a Novel CD45 Target

• Understanding the impact that broader patient impact will have on the haem space
• Outlining the lead selection process to identify a target restricted to the hematopoietic system, ensuring safe and efficacious therapies
• Presenting preclinical data from the TCR discovery process

Speakers:

Mollie Jurewicz

Director - TCR & Autoimmune Discovery

TScan Therapeutics